Recently, Yellwin announced the completion of a nearly 100-million-yuan A+ round of financing. This round of financing was led byNoyu CapitalLeading investment,Zhonan Ventures and Qichen Holdings participated in the investment, while existing shareholders IDG Capital and Yuanhui Chuangyi continued to increase their investments.C Zero Capital served as the exclusive financial advisor for this round of financing. This round of financing is also the second round completed by Yellwin in the same year after completing its Series A financing in April 2023. With the joint support of new and existing shareholders, the company will continue to strengthen the research and development and market promotion of its cardiac surgery and heart failure product lines. Meanwhile, Yellwin is also an angel-incubated enterprise by Hotang Ventures.

Yellwin, established in 2021, is an innovative enterprise dedicated to the research and development of devices in the field of cardiac surgery and heart failure. Based on the founding team's years of clinical experience in cardiac surgery, the company identifies clinical needs and develops multiple medical devices by integrating the current status of related fields. These innovations aim to fill clinical gaps and expedite the trend of China-produced high-end cardiac surgical medical devices replacing imported ones. In 2023, Yellwin consecutively received the titles of "Zhongguancun High-tech Enterprise" and "National High-tech Enterprise."

In the new phase of medical device innovation and development, the leading role of scientists and clinical experts has become increasingly prominent. Independent innovation based on clinical needs and more efficient collaboration between medical and engineering fields are effective ways to break through the "internal competition" in the medical device industry.

Yellwin was co-founded by a team of clinical experts in cardiac surgery from Anzhen Hospital, along with senior technical experts from the domestic and international cardiovascular device industry. The team has accumulated over 20 years of clinical and product development experience in cardiac surgery and heart failure. They not only possess extensive experience in the diagnosis and treatment of heart surgery, a deep understanding of clinical pain points and patient needs, but also have profound insights into the current issues and development trends of medical devices in China's cardiovascular field, especially in coronary heart disease.

The team, starting from clinical needs, has been committed to creating products that not only meet the requirements of clinical work but also fill the market gaps in China's medical device-related fields. At the same time, the products align with national healthcare policy directions, which is beneficial for accelerating the innovation process of domestic high-end medical devices in China and helping doctors improve clinical outcomes while reasonably controlling diagnostic and treatment costs.

Since its establishment, the company has consistently adhered to commercialization capabilities and innovation as the core of product development. In a relatively short period, it has rapidly laid out commercially viable products, giving the company the potential to quickly form a closed-loop business model. At the same time, it has balanced investment in innovative flagship products and long-term planning, achieving a perfect equilibrium between rapid commercialization and innovative R&D.

Currently, Yellwin has upcoming products such as a new-generation heart stabilizer, femoral artery-vein catheters, and an intelligent coronary angiography scoring system, which are about to obtain registration certificates and enter the commercial sales phase. The company has also laid out multiple short-cycle rapid commercialization projects in areas like animal experiments and nursing, enhancing its self-sustaining capabilities. Meanwhile, Yellwin is actively increasing continuous investment in its core products, constantly building up its innovative barriers. The quality control system for coronary artery bypass grafting has entered the experimental production stage, while products like the pulsatile left ventricular assist system have completed design finalization. These products will fill clinical gaps in China and accelerate the development of domestic substitution for high-end cardiothoracic medical devices.

Yellwin's self-developed pulsatile percutaneous left ventricular assist device (PVAD) is developed based on the clinical pain points in severe cardiac surgery, while also meeting the treatment needs of patients with cardiogenic shock in cardiology scenarios. Yellwin’s PVAD not only has the advantages of low cost, high safety, and no need for DSA assistance like IABP products, but also addresses the issue of insufficient flow found in traditional pulsatile PVAD products such as IABP and PulseCath. The product aims to complement continuous-flow PVAD products represented by IMPELLA, providing Chinese cardiovascular physicians with a powerful, domestically innovative tool to manage high-risk patients.

Dr. Wenyan Yu, Co-founder and CEO of YellwinRepresentation: In order to "survive," the Yellwin team has always adhered to three core concepts: First, based on the team's more than twenty years of clinical work experience, they explore the "real needs" of clinicians to drive product innovation. Second, leveraging the core team’s decades of device R&D experience in the cardiovascular field, they integrate upstream and downstream resources both domestically and internationally to accelerate the development process. Third, recognizing that even superior medical devices can struggle with visibility, they draw on the market and sales teams' decades of experience in leading companies at home and abroad, combined with the new situation of healthcare anti-corruption, to create a marketing model suitable for a startup team.

Professor Yang Yu, Co-founder and Chief Scientist of YellwinRepresentation: Under the combined influence of centralized procurement, the pandemic, and an aging population, China’s cardiac surgery field is gradually showing two major trends. The first is the increasing supply-demand contradiction between hospitals’ diagnostic and treatment capabilities and patients’ medical needs. The second is the growing trend of patients becoming critically ill and surgeries becoming more complex. Therefore, future innovations in cardiac surgical devices should always adhere to two core principles: how to focus on clinical doctors to reduce surgical difficulty, shorten the learning curve, and improve diagnostic efficiency; and how to focus on the disease itself to enhance the ability to manage critically ill and complex patients. Yellwin’s innovative cardiac surgical devices and pulsatile left ventricular assist systems are product definitions tailored to these trends, striving to create an integrated solution for critically ill cardiac surgery patients.

IDG Capital stated: We believe that the medical-engineering transformation, which is more aligned with clinical needs, is the future trend of medical device development, especially in the cardiovascular industry that we are optimistic about. Yellwin has effectively seized this trend and implemented it with strong team execution, achieving transformation. In the current challenging environment, the ability to successfully advance product development, expand the product portfolio, build a strong team, and secure financing reflects the excellent management capabilities of the Yellwin team.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

 

Related Reading

Tap for more!

Output value exceeding 30 billion in 5 years, major moves by China's leading medical device manufacturer

Latest IPO Progress of Chinese CT Giant

Ophthalmic Instrument Leader: Spin Off China Business for IPO?

The First Artificial Bone Stock, Cross-Border Acquisition

Chinese-produced Vascular Intervention Platform Completes Over 100 Million Yuan in Series B Financing

Endoscopy Giant Issues Level I Recall Again

Over 1.4 Billion, Major Move by Leading Chinese Intervention Company

Top 3 Life Science Instrument Giants: Layoffs of 400, Sale of Subsidiaries

May Lead to Explosion, Philips Issues Level One Recall for MRI

Game Changer: China's Leading Imaging Giant Releases High-End MRI Equipment

BusinessBusiness cooperation email: qxzj@landianyiliao.com